PRELUDE THERAPEUTICS INC (PRLD) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$15.10M*; Operating income -$15.45M; Depreciation and amortization $353.00K*.
- 2026-03-31: Basis Reported; EBITDA -$13.79M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$16.93M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$19.99M*; Operating income -$20.42M; Depreciation and amortization $425.00K*.
Complete source-backed ebitda history.
- Available history
- 2019-12-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$15.10M* | -$15.45M | $353.00K* | $5.70M | -264.74%* | $0.00* | -$15.57M* | (m) | $16.13M | (m) | (m) |
|---|
| 2026-03-31 | Reported | -$13.79M | (m) | (m) | (m) | -301.00% | $0.00 | -$21.68M | (m) | $13.60M | (m) | (m) |
|---|
| 2025-12-31 | Reported | -$16.93M | (m) | (m) | (m) | -300.18% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$19.99M* | -$20.42M | $425.00K* | $6.50M | -307.58%* | $0.00* | -$19.11M* | (m) | $21.71M | (m) | (m) |
|---|
| 2025-06-30 | Reported | -$31.76M* | -$32.19M | $433.00K* | $0.00 | (m) | $20.00K* | -$26.07M* | (m) | $25.78M | (m) | (m) |
|---|
| 2025-03-31 | Reported | -$34.17M | (m) | (m) | (m) | (m) | $47.00K | -$34.23M | (m) | $28.82M | (m) | (m) |
|---|
| 2024-12-31 | Reported | -$33.34M | (m) | (m) | (m) | -833.55% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$33.97M* | -$34.38M | $405.00K* | $3.00M | -1132.37%* | $63.00K* | -$27.30M* | (m) | $29.46M | (m) | (m) |
|---|
| 2024-06-30 | Reported | -$36.71M* | -$37.16M | $452.00K* | (m) | (m) | $359.00K* | -$23.06M* | (m) | $29.51M | (m) | (m) |
|---|
| 2024-03-31 | Reported | -$33.92M | (m) | (m) | (m) | (m) | $289.00K | -$31.79M | (m) | $27.41M | (m) | (m) |
|---|
| 2023-12-31 | Reported | -$37.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$33.11M* | -$33.38M | $279.00K* | (m) | (m) | $591.00K* | -$25.68M* | (m) | $26.26M | (m) | (m) |
|---|
| 2023-06-30 | Reported | -$32.12M* | -$32.40M | $281.00K* | (m) | (m) | $983.00K* | -$27.67M* | (m) | $24.97M | (m) | (m) |
|---|
| 2023-03-31 | Reported | -$28.84M | (m) | (m) | (m) | (m) | $810.00K | -$30.13M | (m) | $21.83M | (m) | (m) |
|---|
| 2022-12-31 | Reported | -$33.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2022-09-30 | Reported | -$30.07M* | -$30.41M | $337.00K* | (m) | (m) | $916.00K* | -$20.44M* | (m) | $22.89M | (m) | (m) |
|---|
| 2022-06-30 | Reported | -$29.14M* | -$29.46M | $318.00K* | (m) | (m) | $758.00K* | -$18.47M* | (m) | $21.31M | (m) | (m) |
|---|
| 2022-03-31 | Reported | -$29.98M | (m) | (m) | (m) | (m) | $952.00K | -$21.89M | (m) | $22.82M | (m) | (m) |
|---|
| 2021-12-31 | Reported | -$32.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2021-09-30 | Reported | -$30.57M* | -$30.84M | $266.00K* | (m) | (m) | $659.00K* | -$21.77M* | (m) | $22.72M | (m) | (m) |
|---|
| 2021-06-30 | Reported | -$27.72M* | -$27.92M | $199.00K* | (m) | (m) | $381.00K* | -$19.91M* | (m) | $22.41M | (m) | (m) |
|---|
| 2021-03-31 | Reported | -$21.81M | (m) | (m) | (m) | (m) | $986.00K | -$16.14M | (m) | $16.47M | (m) | (m) |
|---|
| 2020-12-31 | Reported | -$19.31M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2020-09-30 | Reported | -$18.00M* | -$18.14M | $142.00K* | (m) | (m) | $170.00K* | -$12.51M* | (m) | $15.29M | (m) | (m) |
|---|
| 2020-06-30 | Reported | -$11.30M* | -$11.44M | $135.00K* | (m) | (m) | $42.00K* | -$8.90M* | (m) | $9.78M | (m) | (m) |
|---|
| 2020-03-31 | Reported | -$9.61M | (m) | (m) | (m) | (m) | $80.00K | -$9.92M | (m) | $8.54M | (m) | (m) |
|---|
| 2019-12-31 | Reported | -$9.97M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2019-09-30 | Reported | (m) | -$6.88M | (m) | (m) | (m) | (m) | (m) | (m) | $5.49M | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$102.86M | (m) | (m) | (m) | -847.24% | $67.00K | -$56.30M | (m) | $94.30M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$137.94M | (m) | (m) | (m) | -1970.60% | $764.00K | -$102.89M | (m) | $118.00M | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | -$131.11M | (m) | (m) | (m) | (m) | $3.51M | -$107.06M | (m) | $103.39M | (m) | (m) |
|---|
| 2022-12-31 | Reported | -$122.22M | (m) | (m) | (m) | (m) | $3.02M | -$83.73M | (m) | $92.89M | (m) | (m) |
|---|
| 2021-12-31 | Reported | -$112.82M | (m) | (m) | (m) | (m) | $2.32M | -$83.53M | (m) | $86.78M | (m) | (m) |
|---|
| 2020-12-31 | Reported | -$58.22M | (m) | (m) | (m) | (m) | $621.00K | -$46.18M | (m) | $48.18M | (m) | (m) |
|---|
| 2019-12-31 | Reported | -$27.73M | (m) | (m) | (m) | (m) | $780.00K | -$25.66M | (m) | $24.28M | (m) | (m) |
|---|